Lower incidence of acute graft-versus-host disease with post-transplantation cyclophosphamide compared to anti-thymocyte globulin in higher-risk myelodysplastic syndrome-Reference-Cited by-同舟云学术

Lower incidence of acute graft-versus-host disease with post-transplantation cyclophosphamide compared to anti-thymocyte globulin in higher-risk myelodysplastic syndrome

Published:2024-07-08 Issue:9 Volume:59 Page:1329-1331
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Choi Eun-Ji^ORCID,Han Jin-Hee^ORCID,Park Hyunkyung,Park Han-Seung,Choi Yunsuk,Lee Jung-Hee,Lee Kyoo-Hyung,Lee Young-Shin,Kang Young-Ah,Jeon Mijin^ORCID,Kang Hyeran,Woo Ji Min,Lee Je-Hwan^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41409-024-02364-6.pdf

Reference11 articles.

1. Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641–50.

2. Fletcher RE, Nunes NS, Patterson MT, Vinod N, Khan SM, Mendu SK, et al. Posttransplantation cyclophosphamide expands functional myeloid-derived suppressor cells and indirectly influences Tregs. Blood Adv. 2023;7:1117–29.

3. Moiseev IS, Pirogova OV, Alyanski AL, Babenko EV, Gindina TL, Darskaya EI, et al. Graft-versus-host disease prophylaxis in unrelated peripheral blood stem cell transplantation with post-transplantation cyclophosphamide, tacrolimus, and mycophenolate mofetil. Biol Blood Marrow Transplant. 2016;22:1037–42.

4. Brissot E, Labopin M, Moiseev I, Cornelissen J, Meijer E, Van Gorkom G, et al. Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors. J Hematol Oncol. 2020;13:1–10.

5. Jimenez Jimenez A, Komanduri K, Brown S, Wang T, Pereira D, Goodman M, et al. Improved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant. Blood Adv. 2022;6:4491–500.